Revenue YoY
+1.36%
Operating Income YoY
-13.67%
Net Income YoY
-4.80%
Net Margin Δ
-79 bps
Net income bridge for Pfizer (PFE) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: −$376.00M-4.80%
Profit bridge breakdown for Pfizer (PFE) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | $7.87B | — |
| Revenue | $852.00M | +226.6% |
| Cost of Revenue | $1.25B | +331.4% |
| Operating Expenses | −$4.45B | -1183.2% |
| Other Income / Expense | $2.87B | +763.6% |
| Income Tax | −$894.00M | -237.8% |
| Net Income | $7.49B | — |
- Prior Net Income$7.87B
- Revenue$852.00M
- Cost of Revenue$1.25B
- Operating Expenses−$4.45B
- Other Income / Expense$2.87B
- Income Tax−$894.00M
- Net Income$7.49B
Identity residual: −$2.00M (delta between driver sum and reported ΔNI)
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement